ONLINE Special Article Managing central venous access devices in cancer patients: A practice guideline
Abstract
In cancer care, central venous access devices (CVADs) are used to safely manage patients undergoing long-term systemic treatment. CVADs are also used to ensure the safe delivery of other agents, biotherapy and supportive therapies. Nursing practice is often driven by policies and procedures that may or may not be evidence-based. Prevention of catheter-related intraluminal thrombosis is essential for quality care. Therefore, there is a need for evidence-based standardized protocols across the system. To address the issue, our group conducted a systematic review of the existing literature, which addressed the following questions:
- To prevent catheter-related intraluminal thrombosis and local or systemic catheter-related infection, minimize the need to replace devices, and enhance quality of life of adults with cancer:
- Should CVADs be locked with heparin or saline?
- What volume and strength of solution should be used to lock CVADs?
- How frequently should CVADs be locked or flushed?
- What type of catheter should be used?
Full Text:
PDFReferences
Biffi, R., De, B.F., Orsi, F., Pozzi, S., Arnaldi, P., Goldhirsch, A., et al.
(2001). A randomized, prospective trial of central venous ports
connected to standard open-ended or Groshong catheters in adult
oncology patients. Cancer, 92(5), 1204-1212.
Bow, E.J., Kilpatrick, M.G., & Clinch, J.J. (1999). Totally
implantable venous access ports systems for patients receiving
chemotherapy for solid tissue malignancies: A randomized controlled
clinical trial examining the safety, efficacy, costs, and
impact on quality of life. J Clin Oncol, 17(4), 1267.
Brown-Smith, J.K., Stoner, M.H., & Barley, Z.A. (1990). Tunnelled
catheter thrombosis: Factors related to incidence. Oncol Nurs
Forum, 17(4), 543-549.
Camp-Sorrell, D. (2004). Access device guidelines:
Recommendations for nursing practice and education (2nd
ed.). Pittsburgh, PA: Oncology Nursing Society.
Canadian Intravenous Nurses Association. (1999). Intravenous therapy
guidelines (2nd ed.). Pembroke, ON: Pappin
Communications.
Carde, P., Cosset-Delaigue, M.F., Laplanche, A., & Chareau, I.
(1989). Classical external indwelling central venous catheter versus
totally implanted venous access systems for chemotherapy
administration: A randomized trial in 100 patients with solid
tumours. Euro J Cancer Clin Oncol, 25(6), 939-944.
Centres for Disease Control and Prevention. (2002). Guidelines for the
prevention of intravascular catheter-related infections. MMWR
Recomm Rep, 51, 1-29, Report No.RR-10. Retrieved November
, from http://www.cdc.gov/mmwr/PDF/rr/rr5110.pdf
Cortelezzi, A., Fracchiolla, N.S., Maisonneuve, P., Moia, M.,
Luchesini, C., Ranzi, M.L., et al. (2003). Central venous catheterrelated
complications in patients with haematological malignancies:
A retrospective analysis of risk factors and prophylactic measures.
Leuk Lymphoma, 44(9), 1495-1501.
Craft, P.S., May, J., Dorigo, A., Hoy, C., & Plant, A. (1996). Hickman
catheters: Left-sided insertion, male gender, and obesity are associated
with an increased risk of complications. Aust N Z J Med,
(1), 33-39.
De Cicco, M., Matovic, M., Balestreri, L., Panarello, G., Fantin, D.,
Morassut, S., et al. (1997). Central venous thrombosis: An early
and frequent complication in cancer patients bearing long-term
silastic catheter. A prospective study. Thromb Res, 86(2), 101-
Eastridge, B.J., & Lefor, A.T. (1995). Complications of indwelling
venous access devices in cancer patients. J Clin Oncol, 13(1),
-238.
Gleeson, N.C., Fiorica, J.V., Mark, J.E., Pinelli, D.M., Hoffman,
M.S., Roberts, W.S., et al. (1993). Externalized Groshong
catheters and Hickman ports for central venous access in gynecologic
oncology patients. Gynaecology Oncol, 51(3), 372-376.
Groeger, J.S., Lucas, A.B., Coit, D., LaQuaglia, M., Brown, A.E.,
Turnbull, A., et al. (1993). A prospective, randomized evaluation
of the effect of silver impregnated subcutaneous cuffs for preventing
tunnelled chronic venous access catheter infections in cancer
patients. Ann Surg, 218(2), 206-210.
Groeger, J.S., Lucas, A.B., Thaler, H.T., Friedlander-Klar, H., Brown,
A.E., Kiehn, T.E., et al. (1993). Infectious morbidity associated
with long-term use of venous access devices in patients with cancer.
Ann Intern Med, 119(12), 1168-1174.
Heeger, P.S., & Backstrom, J.T. (1986). Heparin flushes and thrombocytopenia.
Annals of Internal Medicine, 6, 105, 143.
Heit, J.A., O’Fallon, W.M., Petterson, T.M., Lohse, C.M., Silverstein,
M.D., Mohr, D.N., et al. (2002). Relative impact of risk factors for
deep vein thrombosis and pulmonary embolism: A populationbased
study. Arch Intern Med, 162(11), 1245-1248.
Howell, P.B., Walters, P.E., Donowitz, G.R., & Farr, B.M. (1995).
Risk factors for infection of adult patients with cancer who have
tunnelled central venous catheters. Cancer, 75(6), 1367-1375.
Intravenous Nurses Society. (2000). Infusion nursing: Standards of
practice. J Intraven Nurs, 23(Suppl. 6), S1-88.
Johansson, E., Bjorkholm, M., Bjorvell, H., Hast R., Takolander, R.,
Olofsson, P., et al. (2004). Totally implantable subcutaneous port
system versus central venous catheter placed before induction
chemotherapy in patients with acute leukaemia-a randomized
study. Support Care Cancer, 12(2), 99-105.
Kadidal, V.V., Mayo, D.J., & Horne, M.K. (1999). Heparin-induced
thrombocytopenia (HIT) due to heparin flushes: A report of three
cases. J Intern Med, 246(3), 325-329.
Kappers-Klunne, M.C., Degener, J.E., Stijnen, T., & Abels, J. (1989).
Complications from long-term indwelling central venous catheters
in hematologic patients with special reference to infection.
Cancer, .64(8), 1747-1752.
Kelly, C., Dumenko, L., McGregor, S.E., & McHutchion, M.E.
(1992). A change in flushing protocols of central venous catheters.
Oncol Nurs Forum, 19(4), 599-605.
Kelton, J.G. (2005). The pathophysiology of heparin-induced thrombocytopenia:
Biological basis for treatment. Chest, 127(2 Suppl.),
S-20S.
Keung, Y.K., Watkins, K., Chen, S.C., Groshen, S., Silberman, H., &
Douer, D. (1994). Comparative study of infectious complications
of different types of chronic central venous access devices.
Cancer, 73(11), 2832-2837.
Minassian, V.A., Sood, A.K., Lowe, P., Sorosky, J.I., Al-Jurf, A.S., &
Buller, R.E. (2000). Long-term central venous access in gynecologic
cancer patients. J Am Coll Surg, 191(4), 403-409.
Mueller, B.U., Skelton, J., Callender, D.P., Marshall, D., Gress, J.,
Longo, D., et al. (1992). A prospective randomized trial comparing
the infectious and non-infectious complications of an externalized
catheter versus a subcutaneously implanted device in cancer
patients. J Clin Oncol, 10(12), 1943-1948.
Nightingale, C.E., Norman, A., Cunningham, D., Young, J., Webb, A.,
& Filshie, J. (1997). A prospective analysis of 949 long-term central
venous access catheters for ambulatory chemotherapy in
patients with gastrointestinal malignancy. Euro J Cancer, 33(3),
-403.
Pasquale, M.D., Campbell, J.M., & Magnant, C.M. (1992). Groshong
versus Hickman catheters. Surg Gynaecology Obstet, 174(5),
-10.
Pegues, D., Axelrod, P., McClarren, C., Eisenberg, B.L., Hoffman,
J.P., Ottery, F.D., et al. (1992). Comparison of infections in
Hickman and implanted port catheters in adult solid tumour
patients. J Surg Oncol, 49(3), 156-162.
Pellowe, C.M., Pratt, R.J., Harper, P., Loveday, H.P., Robinson, N.,
Jones, S.R., et al. (2003). Evidence-based guidelines for preventing
healthcare-associated infections in primary and community
care in England. J Hosp Infect, 55(Suppl. 2), S2-127.
Pratt, R.J., Pellowe, C., Loveday, H.P., Robinson, N., Smith, G.W.,
Barrett, S., et al. (2001). The epic project: Developing national evidence-
based guidelines for preventing healthcare associated infections.
Phase I: Guidelines for preventing hospital-acquired infections.
Department of Health (England). J Hosp Infect, .47 Suppl.,
S3-82.
Raad, I., Davis, S., Becker, M., Hohn, D., Houston, D., Umphrey, J.,
et al. (1993). Low infection rate and long durability of nontunneled
silastic catheters. A safe and cost-effective alternative for
long-term venous access. Arch Intern Med, .153(15), 1791-
Registered Nurses Association of Ontario. (2004). Assessment and
device selection for vascular access. Retrieved November 2004,
from http://www.rnao.org/bestpractices/PDF/BPG_assess_
device_select_vascular.pdf
Schmitt, B.P, & Adelman, B. (1993). Heparin-associated thrombocytopenia:
A critical review and pooled analysis. American Journal
of Medical Science, 305, 208.
Shelton, B.K. (2000). Evidence-based care for the neutropenic patient
with leukemia. Semin Oncol Nurs, 19(2), 133-141.
Sotir, M.J., Lewis, C., Bisher, E.W., Ray, S.M., Soucie, J.M., &
Blumberg, H.M. (1999). Epidemiology of device-associated infections
related to a long-term implantable vascular access device.
Infect Control Hosp Epidemiol, 20(3), 187-191.
Tesselaar, M.E., Ouwerkerk, J., Nooy, M.A., Rosendaal, F.R., &
Osanto, S. (2004). Risk factors for catheter-related thrombosis in
cancer patients. Euro J Cancer, 40(15), 2253-2259.
Verso, M., & Agnelli, G. (2003). Venous thromboembolism associated
with long-term use of central venous catheters in cancer
patients. J Clin Oncol, 21(19), 3665-3675.
Walder, B., Pittet, D., & Tramer, M.R. (2002). Prevention of bloodstream
infections with central venous catheters treated with antiinfective
agents depends on catheter type and insertion time: evidence
from a meta-analysis. Infect Control Hosp Epidemiol,
(12), 748-756.
Walshe, L.J., Malak, S.F., Eagan, J., & Sepkowitz, K.A. (2002).
Complication rates among cancer patients with peripherally inserted
central catheters. J Clin Oncol, 20(15), 3276-3281.
Warner, B.W., Haygood, M.M., Davies, S.L., & Hennies, G.A.
(1996). A randomized, prospective trial of standard Hickman compared
with Groshong central venous catheters in pediatric oncology
patients. J Am Coll Surg, 183(2), 140-144.
Refbacks
- There are currently no refbacks.